IL1B and Hepatic fibrosis: Given that IL‐1β promotes HSC differentiation into myofibroblasts (Gieling et al., 2009), it is conceivable that inhibition of IL‐1β by MCC950 may explain the therapeutic effect of NLRP3 inhibition on age‐related liver fibrosis.